Business

iRhythm Technologies Announces Second Quarter 2020 Financial Results

SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the

articleIrhythm Holdings, Inc.August 6, 20205/company/irhythm-technologies-inc/news/irhythm-technologies-announces-second-quarter-2020-financial-results-2020-08-06
iRhythm Technologies Announces Second Quarter 2020 Financial Results

About this update from Irhythm Holdings, Inc.

[{"type":"text","content":"SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months ended June 30, 2020.\n Second Quarter 2020 Summary Revenue of $50.9 million- 3% decrease compared to second quarter 2019- 20% decrease compared to first quarter 2020 Gross margin was 69.6%- 560 basis point year-over-year contraction “Despite the challenges presented by the pandemic, we have continued to deliver our Zio service without interruption to the physicians and patients that rely on it. Our team recognized the need for high quality care has never been greater and I could not be prouder of the commitment we have demonstrated,” said Kevin King, CEO. “Second quarter results were encouraging, despite the COVID-19 impact felt early in the quarter. We saw a steady pace of recovery in registration rates throughout the quarter that exceeded our initial expectations. “Importantly, we believe we continued to penetrate the market and take share as an acute shift away from Holter monitoring took place. Our digital platform is well suited to deliver services in a virtual environment, with a single-use Zio device and home enrollment capability. We expect it will remain an important component of many of our accounts’ workflows going forward. We also saw significant traction with Zio AT, signaling the increasing value our complete platform solution provides in streamlining workflows across cardiac monitoring needs. “While we are encouraged by our recent rebound, the macro environment remains uncertain and several market factors could result in suppressed demand through the rest of 2020. We are managing our business for the long-term with planned investments to drive growth and profitability and remain as confident as ever in the durability of our business,” concluded King. Second Quarter Financial ResultsRevenue for the three months ended June 30, 2020 decreased 3% to $50.9 million, from $52.4 million during the same period in 2019. The decrease was primarily due to lower volumes but was slightly offset by increased ASP. Gross profit for the second quarter of 2020 was $35.4 million, or 69.6% gross margin, compared to $39.4 million, or gross margin of 75.2%, during the same period in 2019. Operating expe...

More updates from Irhythm Holdings, Inc.